Using MRI to predict brain changes in Alzheimer's disease
Quantitative Susceptibility Mapping (QSM) as a Non-Invasive Imaging Biomarker for Predicting Neurodegeneration in Alzheimer's Disease
['FUNDING_R21'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-10126496
This study is testing a new type of MRI scan that looks at iron levels in the brain to help predict changes in Alzheimer's disease, and it's for people who want to contribute to better understanding and managing this condition.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10126496 on ClinicalTrials.gov |
What this research studies
This research aims to develop a non-invasive MRI technique called quantitative susceptibility mapping (QSM) to predict neurodegeneration in Alzheimer's disease (AD). By measuring iron levels in the brain, which are linked to the progression of AD, the researchers will correlate QSM results with traditional MRI findings. This approach seeks to enhance the understanding of how neurodegeneration occurs in AD and could lead to better patient management strategies. Participants may undergo MRI scans to help validate this new imaging biomarker.
Who could benefit from this research
Good fit: Ideal candidates for this research are elderly individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new way to predict the progression of Alzheimer's disease, potentially leading to earlier interventions and improved patient outcomes.
How similar studies have performed: Previous research has indicated that iron levels in the brain can be a significant predictor of cognitive decline in Alzheimer's patients, suggesting that this approach has potential based on earlier findings.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, YI — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: WANG, YI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer's Disease, Alzheimer disease